Key Points STAAR Surgical authorized the repurchase of up to $50 million of its common stock. The program is expected to run for about 12…
September 25, 2026
September 25, 2026
Novo Nordisk and Nanexa Sign €1.165 Billion Deal to Develop Longer-Acting Injections
Key Points Novo Nordisk has secured an exclusive global license to use Nanexa’s PharmaShell drug-delivery technology for certain peptide-based medicines. The collaboration covers up to…
September 24, 2026
From Hypothesis to Reimbursement: The Cancer Research That Reached Patients in 2026
Research institutions and cancer charities mark World Cancer Research Day every September 24, a designation built on one argument: cancer science needs sustained funding. That…
September 24, 2026
Nuvectis’ NXP200 Receives China Breakthrough Therapy Designation for BRAF V600-Mutant High-Grade Glioma
Key Points Nuvectis Pharma said China’s Center for Drug Evaluation granted Breakthrough Therapy Designation to NXP200 for recurrent or progressive BRAF V600-mutant high-grade glioma. NXP200,…
Key Points Vistagen Therapeutics presented exploratory fasedienol data at Psych Congress 2026 in New Orleans. The analyses focused on participants with very severe social anxiety…
September 23, 2026
Psyence BioMed Invests Up to $5 Million in PsyLabs for Planned U.S. Ibogaine Program
Key Points Psyence Biomedical Ltd. agreed to invest up to $5 million in Psyence Labs Ltd., or PsyLabs. PBM has committed $2.4 million, with up…
September 23, 2026
Armata Pharmaceuticals Receives $3.7 Million in U.S. Department of War Funding for AP-SA02 Phase 3 Study
Key Points Armata Pharmaceuticals received an additional $3.7 million in non-dilutive funding from the U.S. Department of War for its AP-SA02 Phase 3 clinical program….
September 22, 2026
Vistagen Says Fasedienol Nasal Spray Showed Continued Improvement in Social Anxiety Extension Study
Key Points Vistagen released early results from a longer-term study of fasedienol nasal spray for people with social anxiety disorder. Participants could use the treatment…
September 21, 2026
Armata’s AP-SA02 Phage Therapy Shows Genetic Diversity May Improve Activity Against Staph Infections
Key Points Armata Pharmaceuticals will present new AP-SA02 data at ISSSI 2026 showing that controlled genetic diversity in its bacteriophage therapy may help it kill…
Alzheimer’s disease starts long before anyone notices it. The changes in the brain that eventually show up as memory lapses, confusion or personality shifts can…
September 21, 2026
Xenon Pharmaceuticals Sheds 31% as a Psychosis Signal Pauses Two Phase 3 Depression Trials
Xenon Pharmaceuticals (NASDAQ: XENE) delivered good news and bad news in the same press release — and investors priced only the bad. The company submitted…
September 18, 2026
Hong Kong Patent Extends bioAffinity’s CyPath Lung Protection in Asia
bioAffinity Technologies (NASDAQ: BIAF) has received a patent in Hong Kong covering CyPath Lung, its noninvasive lung cancer test. The grant follows a Chinese patent…